DarioHealth Corp. (NASDAQ:DRIO)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

DarioHealth Goes Beyond Diabetes into Hypertension with New Blood Pressure Monitoring System

This new offering from DarioHealth enables users to integrate blood pressure readings into the Dario mobile app to gain better understanding and control of their health.

 

New York, NY, and Caesarea, Israel – July 30, 2019 – DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics innovator, made its official entry into the field of hypertension management today with the launch of the new Dario Blood Pressure Monitoring System as part of its strategy to go beyond diabetes and reach the wider chronic condition spectrum.

 

The Dario Blood Pressure Monitoring System is a medical device composed of a monitor and a blood pressure cuff. It synchronizes with the Dario mobile app which allows users to track their blood pressure and a variety of health markers, together with the daily actions that influence them. Utilizing the Dario Blood Pressure Monitoring System, together with the Dario Blood Glucose Monitoring System, creates a harmonized digital health solution, enabling users to better monitor their health and make data driven choices. Together with Dario’s software and professional coaching, we believe that users with hypertension and diabetes will benefit from a clear broad picture of their condition in a user-friendly format on their iPhone or Android mobile device.

 

For DarioHealth, which began its journey in diabetes management, the expansion into hypertension is a natural one.  High blood pressure currently impacts approximately 75 million Americans including 73.6% of adults with diabetes. By offering a fast, easy way to monitor these two strongly correlated chronic conditions, Dario aims to help more people live healthier lives. Dario also provides healthcare professionals with access to the accumulated information and enables them to adjust their interventions and evaluate their clinical effectiveness based on real world evidence.

 

Like the Dario Blood Glucose Monitoring System, the Dario Blood Pressure Monitoring System is FDA-cleared.

 

The Dario Blood Pressure Monitoring System will be offered as a companion system where the Dario Blood Glucose Monitoring System is available, online and via Dario distributors.

 

“Our diabetes management solution has proven to be a valuable daily companion to those suffering from this chronic condition, and is able to meet their needs and expectations. We have further expanded our offering to address the needs of those with hypertension, providing a sophisticated solution to millions affected by this condition” commented Erez Raphael, CEO of DarioHealth.

 

About DarioHealth Corp.

 

DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way. Our Cross Functional Team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets.

 

Cautionary Note Regarding Forward-Looking Statements

 

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company states that utilizing the Dario Blood Pressure Monitoring System, together with the Dario Blood Glucose Monitoring System, creates a harmonized digital health solution, enabling users to better monitor their health and make data driven  and its belief that users with hypertension and diabetes that utilize Dario’s software and professional coaching will benefit from a clear, broad picture of their condition in a user-friendly format on their iPhone or Android mobile device, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing, joao@mydario.com, +1-347-767-4220

 

Source:  DarioHealth Corp.

DarioHealth USB Type C Connector for the European Android Market Is CE Marked

DarioHealth offers USB-C connector configuration between Android smart mobile devices and the Dario Blood Glucose Meter

 

New York, NY and CAESAREA, Israel – July 25, 2019 – Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C connector is used to transfer power and communication signals between Android smart mobile devices and the Dario meter, and ensures that consumers, beginning with the Europe market region, will receive the same quality user experience with DarioHealth on the latest Android smart phone devices.

 

Android smart mobile device manufacturers differentiate lines of products across their markets aimed at different user populations, with varying product specifications and product price points. The USB-C connector standard is gradually gaining market share over its main predecessor, the micro-USB, in smart mobile devices. By focusing on high-end Android devices, Dario aims to extend its footprint and have the widest market reach. The Dario Blood Glucose Monitoring System is currently used with the Samsung Galaxy and LG family smart mobile Android devices.

 

Erez Raphael, Chairman and CEO of DarioHealth, commented, “Dario is always looking to stay ahead of the curve and meet the latest technological developments in the market head on. Current mobile technology is rapidly embracing the USB-C standard and we have been working tirelessly to bring a solution that accommodates this protocol. We are proud that our organization has worked with speed and agility to ensure connectivity to the latest Android devices. This significant milestone will allow us to open a whole new market segment and re-engage with former-Dario users who now have the newest Android devices. This is a big breakthrough for us in the European market as an estimated 60 million people have diabetes in Europe. Now more consumers in Europe can benefit from the Dario digital therapeutics solution through their smartphone.”

 

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way.

 

DarioHealth’s cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets.

 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company states that it by focusing on high-end Android devices, it aims to extend its footprint and have the widest market reach, that the approval of USB-C connector is a significant milestone that will allow it to open a whole new market segment and re-engage with former-Dario users who now have the newest Android devices and that more consumers in Europe can benefit from the Dario digital therapeutics solution through their smartphone, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-347-767-4220

 

SOURCE DarioHealth Corp.

About DarioHealth Corp.


 

Live Therapeutics for Better Life
Formulating Digital Therapies One Person at a Time

 

The Dario Difference

DarioHealth delivers evidence-based, personalized digital therapeutic interventions for the chronic condition spectrum, giving people the tools, technology, data, and support they need to manage their health every day.

 

DarioHealth Corp. is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day in age, knowledge of health and treatment is being democratized and we believe people deserve to know everything about their own health, and at the same time have the best tools to manage their treatment.

 

DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed unique ways for people to analyze and personalize their chronic disease management. DarioHealth’s approach has taken the best of both worlds – the world of the wearable market, which is projected to reach $51.6B in just a few years, and the monitoring market that is climbing toward the $30B mark* – and flipped traditional health upside down. We are moving from periodic data to continuous data, from general treatment to personalized treatment, and from theory-driven solutions to adapted data & AI/ML technology. DarioHealth’s solutions span the full spectrum of disease monitoring, management, populations, and engagement.

 

What truly makes DarioHealth a remarkable investment opportunity is the fact that it has steadily grown from being a user-centric, direct-to-consumer company to a mature organization that is fully data-driven and able to provide a wide-range of managed care solutions. At the hub of it all is DarioHealth’s proprietary engagement platform, which has been painstakingly built by carefully monitoring and analyzing big data. Today, DarioHealth boasts phenomenal solutions and automated, full-suite services for the biggest players in the diabetes care management space.

 

 

Dario Blood Glucose Monitoring System


 

Smart pocket-sized device.

Fit for anyone, everywhere, and on the go.

 

 

Highly accurate and fast measurements.

Get results in less than 6 seconds.

 

 

Small drop of blood – only 0.3 μl required.

 

 

 

No cables, no batteries, no hassles.

 

 

 

Automatically records your blood glucose measurements and provides analysis of your condition.

 

 

 

Easily tracks key diabetes metrics, including carb counting, physical activity, and medication intake.

 

 

 

Share real-time information and personalized reports with caregivers and family members.

 

 

 

Built-in emergency hypo alert with GPS location for peace of mind.

 

 

 


 

 

Our Story

 

With tens of thousands of active users worldwide and proven clinical outcomes, DarioHealth is a global digital therapeutics solution leader revolutionizing the way people manage their chronic conditions.

 

Built for and around the user, Dario has created individualized solutions that combine best practices in digital technologies, analytics, hardware, and personal coaching that gently instructs, encourages, and inspires users…

 

To self-manage their health day to day.

 

 

What Makes Dario Different?

 

At Dario, the user always comes first. From designing the medical hardware and mobile applications to defining the communications and coaching, Dario’s goal is to create solutions that engage, inspire and motivate users to make Dario a part of their daily journey towards healthy living.

 

Every user is different. And every day is different. When self-monitoring a chronic condition, having accurate, personal information available in real-time is critical for adapting to the fluctuations of daily life.

 

Who Is Dario For?

 

People who want to understand how their everyday life impacts their personal health, and what actions they can take to improve their health, how to better collaborate with healthcare providers and to live their life on their own terms.

 

Businesses looking to increase employee satisfaction, loyalty, and productivity with fewer health-related absences can take advantage of Dario’s services for employers.

 

Healthcare Providers wanting to boost patient compliance will find that Dario’s interactive services allow for greater monitoring capabilities, and the means to engage with patients to offer the right treatment at the right time.

 

Health Plans seeking better patient outcomes and lower costs will value Dario’s solutions that encourage patients to be more involved in managing their conditions, and proactively take preventative measures that reduce risk, emergency room visits, and preventable hospitalization.

 

And the results speak for themselves. Dario’s user-focused, user-friendly solutions have been shown to help people achieve better health outcomes*. By creating state-of-the-art solutions that help people improve their quality of life, Dario is helping to create a happier, healthier world, one person at a time.

 

* Reference, ADA Poster: “T2D Users of a Digital Diabetes Management System Experience a Shift from Greater than 180 mg/dL to Normal Glucose Levels with Sustainable Results” (ADA 2018 76-LB)

 

A Personal Approach with Global Reach

 

The world leading Dario Blood Glucose Monitoring System has US FDA clearance and approval from the European CE, Health Canada, and Australia’s TGA. It is commercially available in the United States, Canada, the United Kingdom, Germany, Italy, and Australia.

 

DarioHealth is rapidly moving into new geographic markets and chronic conditions such as hypertension, stress management and obesity.

 

Source:  https://www.dariohealth.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for DarioHealth Corp. current news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF DarioHealth Corp.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!